Phosphodiesterase inhibitors: Effectiveness and new applications;Fosfodiësteraseremmers: Effectiviteit en nieuwe toepassingen

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 29, 2006, Pages 1613-1616

  Van Driel, M F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; ISCHEMIC HEART DISEASE; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; REVIEW; SEXUAL BEHAVIOR;

CARBOLINES; CORONARY DISEASE; HUMANS; HYPERTENSION; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSTATIC HYPERPLASIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 33746495629     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Lycklama à Nijeholt AAB. De erectiepil. Ned Tijdschr Geneeskd. 1998;142:2332-3.
2. Hengeveld MW. Somatisering van erectiestoornissen door de komst van sildenafil. Ned Tijdschr Geneeskd. 1998;142:2333-6.
3. Meuleman EJH, Berkel JThH van, Rabsztyn P, Damen L. Sildenafil (Viagra) voor de behandeling van erectiestoornissen. Ned Tijdschr Geneeskd. 1998;142:2337-40.
4. Grootheest AC van, Straus SMJM, Heeringa M. Bijwerkingen van sildenafil: resultaten van twee jaar praktijkervaring. Ned Tijdschr Geneeskd. 2001;145:526-9.
5. Incrocci L, Hop WCJ, Slob AK. Gunstig effect van sildenafil op erectiele disfunctie bij patiënten na radiotherapie voor prostaatkanker; gerandomiseerd, dubbelblind, placebogecontroleerd en gekruist onderzoek. Ned Tijdschr Geneeskd. 2003;147:1687-90.
6. Butcher RW, Sutherland EW. Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem. 1962;237:1244-50.
7. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96:257-80.
8. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov. 2002;1:674-82.
9. Taher A, Stief CG, Raida M, Jonas U, Forsmann WG. Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int J Impot Res. 1996;4 (Suppl 2):11.
10. Küthe A, Wiedenroth A, Mägert HJ, Ückert S, Forssmann WG, Stief CG, et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol. 2001;165:280-3.
11. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med. 2004;1:161-7.
12. Montorsi F, Verheyden B, Meuleman E, Jünemann K-P, Moncada I, Valiquette L, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45:339-44.
13. Van Ahlen H, Zumbé J, Stauch K, Landen H. The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study - results from 29358 German patients. J Int Med Res. 2005;33: 337-48.
14. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res. 2002;7:435-46.
15. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther. 2003;25: 2709-23.
16. Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther. 2003; 25:2724-37.
17. Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol. 2004; 45:499-507.
18. Porst H, Kleingarn M, Arnds S. The three PDE5 inhibitors sildenafil, tadalafil and vardenafil - results of a comparative preference trial in 222 patients with erectile dysfunction. J Urol. 2004;171(Suppl 4): 315.
19. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int. 2005;96: 1323-32.
20. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol. 2004;14:367-73.
21. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med. 2005;2:675-84.
22. Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P, et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med. 2005;2:699-708.
23. Goldstein I, Fisher WA, Sand M, Rosen RC, Mollen M, Brock G, et al. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. J Sex Med. 2005;2:819-32.
24. Ichikawa T, Takao A, Manabe D, Saegusa M, Tanimoto R, Aramaki K, et al. The female partner's satisfaction with sildenafil citrate treatment of erectile dysfunction. Int J Urol. 2004;11:755-62.
25. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urology. 2004;63:762-7.
26. Heiman JR, Talley DR, Bailen JL, Shumel B, Pace CR, Creanga DL, et al. Female partners of men with erectile dysfunction treated with sildenafil citrate report greater satisfaction and enjoyment from sexual intercourse. A multicentre, randomized, double-blind, placebo-controlled study. J Urol. 2005;173:S5.